Search company, investor...

Predict your next investment

Summit Pharmaceuticals International company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
summitpharma.co.jp

See what CB Insights has to offer

Investments

3

Partners & Customers

6

About Summit Pharmaceuticals International

Summit Pharmaceuticals International, a group company of Sumitomo Corporation, provides high-quality integrated products and services to the pharmaceutical industry, from research equipment and bioresources for drug discovery, pharmaceutical licensing, and research alliance support, to manufacturing of APIs, intermediates for pharmaceuticals, generic drugs, and biologics.

Headquarters Location

1-2-2 Hitotsubashi, Chiyoda-ku Sumitomo Corporation Takebashi Building 12F

Tokyo, 100-0003,

Japan

+81 03-5220-1500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Summit Pharmaceuticals International Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Summit Pharmaceuticals International Rank

Latest Summit Pharmaceuticals International News

CytoReason, Summit tap into AI on Japanese drug development effort

Oct 12, 2021

The AI technology firm and pharma services company are joining to help one of the country’s leading pharmaceutical firms develop a promising drug candidate. CytoReason, an Israeli company that uses artificial intelligence (AI) in creating disease models for drug discovery and development, has announced a partnership with Japanese pharma services firm Summit Pharmaceuticals International. Together, the two will provide one of the country’s top pharmaceutical firms with AI-based technology to help advance drug development. According to the collaborators, CytoReason’s AI platform will combine its disease model with clinical data provided by the pharmaceutical company, to help advance understanding of how the drug behaves on a molecular level, compared to similar treatments currently on the market. David Harel, CEO and co-founder of CytoReason, provided details on the collaboration with Outsourcing-Pharma, and what lies ahead. OSP: Please share a short description of CytoReason—who you are, what you do, and any specific accomplishments you might like to point out.​ DH: CytoReason's computational model of the human body simulates human disease on a cellular level and makes human trials more focused and accurate. With CytoReason's proprietary database and AI-led platform, pharma and biotech companies make data-driven decisions in a fraction of the time and cost. To date, six of the world's top ten pharma companies use CytoReason's technology to power their drug programs. OSP: Could you please share how CytoReason and Summit Pharmaceuticals connected—have you partnered with them in the past?​ DH: CytoReason is constantly working to expand its presence globally. With one of the largest pharmaceutical markets in the world and companies known for their impeccable due diligence processes, we are delighted to receive Japan's stamp of approval. SPI has vast experience working with the Japanese pharma market, and an extensive network of relationships in the industry. This is the first major deal that our partnership brings to fruition. We trust there will be many more. OSP: What sets CytoReason apart from other companies operating in this space?​ David Harel, CEO and cofounder, CytoReason DH: CytoReason is a tech company, while most companies in the pharma AI space are biotech companies. CytoReason develops computational disease models that feed on a growing repository of public and proprietary clinical data. Our platform gives different people in the organization - biologists, bioinformaticians, program directors - one place to manage their drug programs and to compare them across patients, diseases, and other drugs in the market. OSP: Similarly, what stands out about Summit Pharmaceuticals among pharma firms?​ DH: Summit Pharmaceuticals, a wholly owned subsidiary of the Sumitomo Corporation, serves as the bridge between the Japanese pharma ecosystem (which consists of tech companies and drug makers) and the global pharma ecosystem. Among other things, SPI leads the introduction of advanced AI technologies into the Japanese market. OSP: Does the collaboration have any short- or long-term goals in your work that you could share with us?​ DH: Our longstanding partnership with SPI provides us with an excellent opportunity to work with other pharma companies in Japan. There’s no better partner than SPI to introduce our cutting-edge technology into the Japanese market. OSP: Are there any specific conditions or therapeutic areas you’ve got in your sights?​ DH: We focus on both immune-mediated and immuno-oncology diseases. Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Summit Pharmaceuticals International Investments

3 Investments

Summit Pharmaceuticals International has made 3 investments. Their latest investment was in Luxna Biotech as part of their Series A on February 2, 2020.

CBI Logo

Summit Pharmaceuticals International Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/10/2020

Series A

Luxna Biotech

$5.84M

Yes

5

12/31/2012

Corporate Minority - III

Subscribe to see more

$99M

Subscribe to see more

10

1/31/2003

Corporate Minority

Subscribe to see more

Subscribe to see more

10

Date

2/10/2020

12/31/2012

1/31/2003

Round

Series A

Corporate Minority - III

Corporate Minority

Company

Luxna Biotech

Subscribe to see more

Subscribe to see more

Amount

$5.84M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

10

10

Summit Pharmaceuticals International Partners & Customers

6 Partners and customers

Summit Pharmaceuticals International has 6 strategic partners and customers. Summit Pharmaceuticals International recently partnered with CytoReason on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/12/2021

Partner

Israel

CytoReason, Summit tap into AI on Japanese drug development effort

DH : Our longstanding partnership with SPI provides us with an excellent opportunity to work with other pharma companies in Japan .

1

10/12/2021

Partner

Israel

Subscribe to see more

Subscribe to see more

10

9/30/2021

Partner

Israel

Subscribe to see more

Subscribe to see more

10

9/30/2021

Partner

Israel

Subscribe to see more

Subscribe to see more

10

10/4/2019

Partner

Germany

Subscribe to see more

Subscribe to see more

10

Date

10/12/2021

10/12/2021

9/30/2021

9/30/2021

10/4/2019

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

Israel

Israel

Israel

Israel

Germany

News Snippet

CytoReason, Summit tap into AI on Japanese drug development effort

DH : Our longstanding partnership with SPI provides us with an excellent opportunity to work with other pharma companies in Japan .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.